Analytical Data
-
Gene name
DYDC2
- Application
-
Alternative Names
DPY30 domain-containing protein 2; DYDC2
-
Species
Human
-
Source
E. coli
-
Tag
C-10*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q96IM9
-
Expression Region
T102-P176
-
Protein Length
Partial
-
Molecular Weight
37 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DYDC2, a member of the DYDC family of proteins, has garnered significant attention in recent years due to its crucial role in cellular processes and potential implications in various diseases. Initially identified as a key player in the regulation of gene expression, DYDC2 is believed to participate in the modulation of RNA stability and translation. Its involvement in stress response pathways has prompted investigations into its function in cellular adaptation to environmental changes. Furthermore, recent studies have suggested a link between DYDC2 dysregulation and several pathological conditions, including cancer and neurodegenerative disorders, highlighting its potential as a therapeutic target. The recombinant expression of DYDC2 allows for detailed structural and functional studies, enabling researchers to unravel the molecular mechanisms underlying its activity. The production of DYDC2 as a recombinant protein not only facilitates enzyme assays and functional analyses but also aids in the development of specific inhibitors or modulators that could pave the way for novel therapeutic approaches. As the understanding of DYDC2 continues to evolve, it holds promise not only for basic research but also for the development of strategies aimed at mitigating the impact of diseases associated with its malfunction.
